从激动剂转换为拮抗剂介导的生长抑素受体诊疗实现更优NET靶向,使原本无法治疗的mNET成功接受(基于LM3的)PRRT:个体内概念验证
一例69岁女性转移性小肠NET G2患者,在生长抑素类似物治疗下进展,[68Ga]Ga-DOTATOC PET/CT示踪剂摄取差而无法行PRRT。改用[68Ga]Ga-NODAGA-LM3 PET/CT后摄取明显改善且足以治疗,遂启动[177Lu]Lu-DOTA-LM3 PRRT,4个周期后观察到阳性反应。该病例展示生长抑素受体拮抗剂显像优于激动剂,并可转化为成功的靶向肽介导放射性核素治疗。
要点
- SSA治疗进展后[68Ga]Ga-DOTATOC PET/CT摄取差,曾使PRRT无法进行。
- [68Ga]Ga-NODAGA-LM3 PET/CT显示摄取明显更佳且足以支持治疗。
- 基于LM3的[177Lu]Lu-DOTA-LM3 PRRT 4个周期后观察到阳性反应。
核心结论
- 该病例显示生长抑素受体拮抗剂显像在诊断上优于激动剂显像,并可直接转化为成功的靶向肽介导放射性核素治疗。
研究设计与样本
- 单个患者(69岁女性)的个体内概念验证病例报告。
主要发现
- 患者为转移性小肠NET G2,初始接受SSA治疗,在SSA治疗下观察到疾病进展。
- [68Ga]Ga-DOTATOC PET/CT示踪剂摄取差,使PRRT无法进行。
- [68Ga]Ga-NODAGA-LM3 PET/CT显示摄取明显更佳且足以支持治疗。
- 启动[177Lu]Lu-DOTA-LM3 PRRT,4个治疗周期后观察到阳性反应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present a case of a 69-year-old woman with metastasized small bowel NET G2 initially treated with somatostatin analogs (SSA). Disease progression was observed under SSA, and poor tracer uptake on [ 68 Ga]Ga-DOTATOC PET/CT precluded peptide receptor radionuclide therapy (PRRT). Subsequently, evaluation with [ 68 Ga]Ga-NODAGA-LM3 PET/CT was performed, which showed markedly better and treatment-sufficient uptake, enabling initiation of PRRT with [ 177 Lu]Lu-DOTA-LM3. After 4 therapy cycles, a positive response was observed. This interesting case nicely demonstrates not only the diagnostic superiority of somatostatin receptor antagonist (over agonist) imaging but also the direct translation into successful targeted peptide-mediated radionuclide therapy.
引用
- Speicher T, Burgard C, Rosar F, et al. Superior NET Targeting by Switch From Agonist to Antagonist-mediated Somatostatin Receptor Theranostics Allowing Successful (LM3-based) PRRT of Otherwise Precluded mNET: Intraindividual Proof-of-concept. Clin Nucl Med. 2025. PMID: 40296275. doi:10.1097/RLU.0000000000005936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。